Answers are grounded in this paper and cite their sources.
Working paper outlines AIMEON, a platform for measuring and optimizing personal time value, indicating potential for innovative applications.
Humanity has possessed a finite, non-renewable resource — time — yet has never developed a system to measure its value, optimize its use, or exchange it as an asset. This paper presents AIMEON, a proposed Temporal Intelligence Platform built upon a unit of personalized time value: the CHRAIME (symbol: Ꞩ). AIMEON combines calendar data, self-reported goals, and optional biometric signals into a composite metric that estimates, for a given interval, how well that time aligned with the individual's own stated priorities. The paper describes the AIMEON ecosystem, including five cooperating software engines (AIMEON DECIDE, AIMEON PLAN, AIMEON GENOME, AIMEON MEASURE, AIMEON INSIGHT), an on-device-first privacy architecture, a phased go-to-market plan, and a long-term, contingent vision for a services marketplace (AIMEPLACE) and a routine-licensing product (AIMEPRINT). It also describes the philosophical framework informing the design (Chronosophy) and states the actual scope and limits of its proposed verifiability mechanisms. This is a systems and design specification paper, not an empirical study, and it is explicit throughout about what is and is not demonstrated.
No takes yet. Share an insight, caveat, or question.
Rashon Rahming (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: